19-20 February, 2019 | San Diego, CA

 

Angle

Expertise Partner

ANGLE’s Parsortix technology enables the capture and harvest of circulating tumor cells from patient blood. The resulting liquid biopsy (simple blood test) provides a powerful tool to deliver personalized cancer care. ANGLE is currently developing its first diagnostic product in the area of ovarian cancer. The Parsortix system has CE Mark regulatory approval in Europe and an FDA approval process is underway in the US.

www.angleplc.com

 

Guardant Health

Program Partner

Guardant Health is a pioneer in non-invasive cancer diagnostics, addressing challenges across the cancer care continuum. The company has raised more than $200 million from leading venture capital firms and in 2014 launched Guardant360, the first comprehensive liquid biopsy for clinical use. Guardant Health is improving therapy selection for advanced cancer patients across the globe using its proprietary cell-free circulating tumor DNA NGS platform. Guardant Health is partnered with biopharmaceutical companies to prospectively screen patients for trial enrollment, develop companion diagnostics to support clinical adoption, and use retrospective analysis for early insights into patient response and tumor evolution, as well as accelerate the development of new therapies.

www.guardanthealth.com

Thermo Fisher Scientific Inc.

Program Partner

Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We support precision medicine from translational research to the development of companion diagnostics with innovative technologies and service through our Thermo Scientific, Applied Biosystems, Invitrogen, Gibco and Ion Torrent brands.

www.thermoscientific.com

 

Randox Biosciences

Program Partner

Randox Biosciences are a highly innovative global leader in clinical diagnostic manufacturing supplying the world’s top CRO’s and biopharmaceutical companies. We have technical expertise in diagnostic and CDx assay development utilising single analyte assays, as well as multiplex assays that test up to 23 biomarkers using one patient sample via our Evidence range of analysers. This utilises our proprietary Biochip Array Technology which was developed using our in house range of antibodies, proteins and conjugates. We also offer a custom development service for all our raw materials for the biopharmaceutical and diagnostic industries. As well as custom assay development, our custom services also include polyclonal and monoclonal development and recombinant antibody fragments (sdAb, scFv, Fab).

www.randoxbiosciences.com

 

Biodesix

Spotlight Partner

Biodesix® is an experienced partner in the field of blood-based molecular diagnostic testing. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by interpreting genomic and proteomic information from both tumor biology and the patient’s immune response. Biodesix enables our partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategiess.

www.biodesix.com

 

For further information please don’t hesitate to send us an email.